ROCHESTER, NY – Vaccinex Inc., a biotechnology company focused on the development of novel immune-based therapeutics, announced today that Ernest Smith, Ph.D., Senior Vice President of Research and Chief Scientific Officer, will present during the 6th annual PEGS protein engineering summit to be held in Boston, Massachusetts. Dr. Smith will present details of Vaccinex’s proprietary selection technology for the identification of novel human antibodies through de novo selection, affinity maturation, and mouse to human conversion. “Our discovery platform has been an important tool for internal and external projects and we are excited to be able to share details of our approach.” said Dr. Smith.
About Vaccinex, Inc.
Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Utilizing its patented ActivMAb® antibody discovery technology, Vaccinex has developed the only library-based antibody discovery technology capable of directly expressing bivalent, fully human antibodies in mammalian cells. The company is building an impressive pipeline of therapeutic antibodies with the potential for effectively treating various autoimmune diseases and cancers. For additional information, please visit the company’s website at www.vaccinex.com.